Miach Orthopaedics is a technology company.
Miach Orthopaedics has raised $30.0M across 1 funding round.
Miach Orthopaedics has raised $30.0M in total across 1 funding round.
Miach Orthopaedics is a medical device company developing bio-engineered implants to restore natural connective tissue, primarily the BEAR® Implant for healing torn anterior cruciate ligaments (ACLs).[1][2][3] It serves patients with ACL injuries and orthopedic surgeons, solving the limitations of traditional reconstruction by enabling the body's own tissue to heal without grafts, which reduces recovery time and preserves natural knee function.[1][2][3] The company has treated nearly 3,000 patients, raised $82.5M in funding including a $20M Series B extension in 2024, and achieved FDA De Novo approval in 2020 as the first device to clinically demonstrate ACL restoration.[1][2][3]
Founded in 2016, Miach Orthopaedics emerged from research by Martha Murray, MD, a pioneer in ACL restoration at Boston Children’s Hospital Department of Orthopaedic Surgery.[1][4] Initial funding came from the NFL Players Association, Boston Children’s Hospital, and the National Institutes of Health, supporting development of the BEAR Implant.[1] Early traction included FDA De Novo approval in 2020—one of the agency's most novel sports medicine devices—and rapid clinical adoption, marking the first ACL treatment innovation in decades.[1][3]
Miach rides the wave of regenerative orthopedics, shifting from invasive reconstructions to biology-driven tissue restoration amid rising sports injuries and demand for faster recoveries.[1][3] Timing aligns with FDA support for novel devices and post-2020 adoption acceleration, fueled by real-world evidence presented at events like AOSSM 2025.[1][4] Market forces include a massive ACL injury market (hundreds of thousands annually in the U.S.), investor confidence ($82.5M raised), and studies validating outcomes, positioning Miach to challenge the 30+ year status quo and influence sports medicine standards.[2][3]
Miach is poised for expanded U.S. commercialization and potential global reach, leveraging recent funding for clinical trials like the Bridge Registry (tracking 2-year outcomes) and patent expansions in ligament repair.[3][4] Trends in personalized medicine, AI-enhanced imaging for implants, and athlete-driven demand will accelerate adoption, potentially establishing BEAR as the new ACL standard.[1][3] As real-world data matures, Miach could redefine orthopedics, enabling more patients to reclaim natural mobility without lifelong graft compromises—echoing its founding mission to let the body heal itself.[1][5]
Miach Orthopaedics has raised $30.0M in total across 1 funding round.
Miach Orthopaedics's investors include Amzak Health Investors.
Miach Orthopaedics has raised $30.0M across 1 funding round. Most recently, it raised $30.0M Series B in January 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2023 | $30.0M Series B | Amzak Health Investors |